Transgene Biotek inks pact with Atral Cipan

23 Jan 2013 Evaluate

Transgene Biotek has inked pact with Atral Cipan of Portugal by signing Tacrolimus Licensing and Technology Transfer agreement. As per the agreement, Atral Cipan will move the products through regular filings with the USFDA and European Medicines Agency (EMEA) for manufacturing and marketing Tacrolimus.

Both companies believe that Transgene’s experience and skills in developing technologies, coupled with the global presence and pharmaceutical experience of Atral Cipan, will expand the commercialization and marketing of Tacrolimus across several developed markets including the US and Europe. 

Transgene Biotek Share Price

3.08 0.08 (2.67%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7189.25
Max Healthcare Inst 1097.95
Narayana Hrudayalay 1916.45
Aster DM Healthcare 635.10
Global Health 1163.75
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×